PD-1/PD-L1 inhibitors in combination with gemcitabine and cisplatin are approved as first-line for the treatment of refractory recurrence and/or metastasis (R/M) NPC in 2021 in China. This evidence concerns the gene CD274 and nasopharyngeal carcinoma.